PreveCol blood test for finding colorectal cancer after a positive stool test
Tests the PreveCol blood test for colorectal cancer in people with positive stool results.
Plain-language title generated from the registry record
Registry title: Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection
Key facts
- Where
- Madrid, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 69 with no symptoms and average risk of bowel cancer. They must have had a positive stool blood test (FIT/FOBT) and be referred for a screening colonoscopy.
- Age
- 50 to 69 years
- Sex
- Women and men can join.
- Disease stage
- No symptoms, average risk of colorectal cancer. No history of adenoma, colorectal cancer or inflammatory bowel disease, and no first-degree relative with colorectal cancer.
- Earlier treatment
- People who had chemotherapy or radiotherapy in the past 5 years, or a polyp removal in the past 5 years, cannot join.
- Biomarker or test result
- A positive FIT/FOBT stool blood test result.
Main reasons for not taking part
- Another type of cancer in the past 5 years
- Chemotherapy or radiotherapy in the past 5 years
- Familial adenomatous polyposis, Lynch syndrome or inflammatory bowel disease
- Polyp removal (polypectomy) in the past 5 years
- Poor bowel preparation for the colonoscopy, or a blood sample that is missing or damaged
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 69 years old?
Source: NCT06703632, who can take part
Where in Spain
- Hospital Universitario Ramón y CajalMadrid, SpainContact: Agustin Albillos, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- ADVANCED MARKER DISCOVERY S.L.
- Trial code
- NCT06703632
- Record updated
- 27 February 2025
- Original description
The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas when used prospectively in the screening population with a previous positive FOBT result, which could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to be answered are:Read full original descriptionShow less
Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection
The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas when used prospectively in the screening population with a previous positive FOBT result, which could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to be answered are:
* Values of efficacy, efficiency, impact and safety of PreveCol. * Values of preferences of participants for screening methods. * Values of PREMs into screening programme.
Participants will provide a blood sample prior to a screening colonoscopy, and complete two questionnaires. They will give their sample, information and clinical data to the investigator or health care personnel.
Inclusion: Participants ages from 50 to 69 years (both included) at the time of informed consent signed; Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form; Participants with a positive result of FIT/FOBT analysis referred to the gastroenterology department who are eligible to undertake colonoscopy as a regular procedure of the colorectal cancer screening programme; Participants asymptomatic, average risk for CRC. Average risk is defined as those individuals who are age 50 or over with no history of adenoma, colorectal cancer, or inflammatory bowel disease, and with no family history of CRC (first degree relatives).
Exclusion: Participants who have developed any another type of cancer in the 5 years prior to their participation in the study; Participants who have previously received chemotherapy or radiotherapy (5 years); Participants previously or currently diagnosed with Familiar Adenomatous Polyposis or Lynch Syndrome or Inflammatory Bowel Disease; Participants who have undergone polypectomy in the previous 5 years; Inadequate intestinal preparation for colonoscopy with BBPS score ≤1 in any colon section, excluding diagnostic of CRC; Hemolysis of blood sample or absence of blood sample; Participants who are arrested at judicial or official request; Participants who are in a dependent personal or non-medical relationship with the Sponsor or the investigator.